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Effects of a portacaval or peritoneovenous shunt on renin in the
hepatorenal syndrome: Ten patients with hepatorenal syndrome
were evaluated before and after creation of a side-to-side porta-
caval shunt or insertion of a peritoneovenous shunt, procedures
which produced an increase in plasma volume and cardiac out-
put. In the seven patients who survived surgery, renal function
improved significantly, plasma renin activity fell from high to
normal levels, and low levels of plasma renin substrate in-
creased. Prior to surgery, blockade of angiotension II by sarala-
sin produced hypotension and an increase in plasma renin activi-
ty, whereas after surgery, saralasin had no effect on blood pres-
sure or renin. Our findings suggest that decreased "effective"
plasma volume may be important in the stimulation of renin re-
lease and possibly in the pathophysiology of renal failure in the
hepatorenal syndrome.
Effet d'un shunt portocave ou péritonéoveineux sur Ia rénine
au cours du syndrome hépatorénal. Dix malades atteints de syn-
drome hépatorénal ont été étudiés avant et après Ia creation
d'une anastomose portocave latérolatérale ou l'insertion d'un
shunt péritonéoveineux, deux procédés qui déterminent une
augumentation du volume plasmatique et du debit cardiaque.
Chez les sept malades qui ont survédu a Ia chirurgie la fonction
rénale a été significativement améliorée, l'activité refine plas-
matique a diminué d'une valeur élvée a une valeur normale
et Ia concentration initialement faible du substrat plasmatique de
Ia rénine a augmente. Avant l'acte chirurgical le blocage
del'angiotensine II par Ia saralasine a produit une hypotension et
une augmentation de l'activité refine plasmatique alors qu'après
Ia chirurgie Ia saralasine n'a plus d'effet sur Ia pression artérielle
ou Ia refine. Nos constatations suggêrent que Ia dimunution du
volume plasmatique "efficace" peut étre importante dans la
stimulation de Ia liberation de rénine et, peut-être, dans Ia
physiopathologie de l'insuffisance rdnale du syndrome hepato-
renal.
Altered intrarenal distribution of blood flow with
a relative decrease in renal cortical perfusion is a
fairly common finding in patients with cirrhosis and
ascites [1—31. In some cases, severe renal vaso-
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constriction with reduction in total renal blood flow
leads to oliguric functional renal failure, termed the
hepatorenal syndrome. The causes of the hepato-
renal syndrome are not clear. In many cases there
are associated systemic hemodynamic derange-
ments [1-4], and in most instances the renin-angio-
tensin system is activated [5—71. The renin system
may be important in man in the regulation of blood
pressure and renal blood flow; its role in the hepato-
renal syndrome, however, remains obscure.
Recovery from the hepatorenal syndrome is rare.
Prolonged improvement in renal function has been
reported, however, in several patients following
construction of a side-to-side portacaval shunt [8-
11] or after insertion of a peritoneovenous shunt
[12-151. In this study, hemodynamic parameters
and components of the renin system were measured
before and after portacaval or peritoneovenous
shunt surgery in ten patients with hepatorenal syn-
drome, seven of whom experienced significant post-
operative improvement in renal function.
Methods
In the period from 1968 to 1977, patients with alco-
holic cirrhosis, ascites and hepatorenal syndrome,
but with evidence of good liver function, were eval-
uated for study. Patients with severe liver dysfunc-
tion or with gastrointestinal bleeding or other fac-
tors which may have contributed to reduced renal
perfusion were excluded. Sixteen patients (repre-
senting approximately 10% of patients seen in con-
sultation for renal failure with cirrhosis) qualified
for this study. Five of these refused to participate
and were treated with continuation of medical ther-
apy. All five died of combined effects of hepatic and
renal failure within one month. One patient accept-
ed for study died before surgery was performed.
Each of the ten remaining patients who partici-
pated in the study was cachectic with massive as-
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Table 1. Preoperative and postoperative hepatic function in patients with hepatorenal syndrome
cites and had oliguric renal failure. Urinary sodium
excretion and urinary osmolality was consistent
with cnterea suggested for diagnosing the hepato-
renal syndrome [111. Preoperative liver function
tests and other clinical data are shown in Tables 1
and 2. The creatinine clearance was less than 20 ml!
mm in all but two patients, and their renal failure
was not responsive to careful medical management,
including plasma volume expansion with i.v. saline
(from 2 to 6 liters) and albumin (from 50 to 200 g)
given over 24 to 36 hours. Patients 1, 2, 4, and 5
required peritoneal dialysis to control azotemia.
Progressive weakness, anorexia, and mild to severe
hepatic encephalopathy ensued in each patient, and
the prognosis for prolonged survival was poor. By
standard classification [16], each of these patients
was a poor surgical risk. The patients (and!or close
relatives) were advised of the very high mortality
rate in persistent oliguric hepatorenal syndrome and
were informed of the risks inherent in the surgery,
of the uncertainty of the outcome, and of the fact
that the efficacy of the procedure in this setting was
unproven.
Five patients (patients 1 through 5) underwent
construction of a side-to-side portavacal shunt or a
mesocaval shunt. In five patients (patients 6
through 10), a peritoneovenous shunt, a silastic
conduit connecting the peritoneal space to the jugu-
lar vein as described by LeVeen et al [17], was im-
planted to chronically transfer ascitic fluid to the
venous system. In patients 6 and 9, the pen-
toneovenous shunt clotted after 12 weeks and 4
weeks, respectively, necessitating a second surgical
procedure. A mesocaval shunt was constructed in
patient 6, and another peritoneovenous shunt was
placed in patient 9.
Creatinine clearance was measured on 24-hour
collections of urine. Plasma renin activity (PRA)
and plasma renin substrate (PRS) were measured
prior to surgery after dietary intake of 10 mEq of
sodium per day for 3 to 5 days and under similar
conditions serially after surgery. Samples were
taken in the morning with the patients supine. PRA
was assayed by the method of Cohen et al [181.
Samples were collected in syringes containing ED-
TA, they were chilled immediately, centrifuged at
Patient
no.
Age,
sex
Time of
testinga
Bilirubin
(0.l_1.2)c
mg/JOOinl
SGOT"
(1_39)e
U/mi
Alkaline
phosphatase
(4_13)e
U/mi
Serum
albumin
(3.4_4.9)c
g/lOOmi
Proth
time
(9.2_l1.2)r
Postsurgical
condition
(period
of follow)
1 48, F Preoperative
8yrpostPCS
0.8
0.5
36
20
25
8
2.3
4.4
16.3
9.5 Well(lOyr)
2 45,F Preoperative
2wkspostPCS
1.0
6.3
30
62
15
11
2.3
3.8
18.1
16.8 Died(2wks)
3 49,F Preoperative
lwk post PCS
1.2
4.1
60
54
19
9
2.5
2.9
16.1
— Died(lwk)
4 46, F Preoperative
1 yr post MCS
2.7
0.9
54
32
12
10
2.8
3.7
11.8
13.0 Well (2.5 yr)
5 56,M Preoperative
I mo post MCS
2.1
24.0
51
80
6
—
2.5
3.3
12.5
32.0 Died(8wks)
6A
6B
60, M Preoperative
2mospostPVS
Preoperative
12 mos post MCA
1.0
1.6
0.9
0.5
22
22
21
30
8
13
8
18
2.9
3.0
3.4
2.8
10.8
9.6
10.7
— Improved (2 yr)
7 47,M Preoperative
6wkspostPVS
1.8
3.2
44
30
23
14
2.9
2.5
13.6
14.4 Died(l0wks)
8 53,M Preoperative
6wks post PVS
0.7
0.8
16
33
14
21
—
2.6
10.1
11.7 Improved (1 /2 yr)
9A
9B
51, F Preoperative
1 mo post PVS
Preoperative
2mospost2ndPVS
1.6
2.0
1.5
1.3
33
27
39
44
25
26
32
27
2.8
2.9
2.9
3.0
9.5
9.2
10.3
10.4 Improved(4mos)
10 56, M Preoperative
3mospostPVS
1.5
1.3
35
30
14
26
2.8
3.0
15.0
13.0 Improved(3mos)
a Abbreviations are PCS, side-to-side portacaval shunt;
b Serum glutamic-oxaloacetic transaminase.
Normal range.
MCS, mesocaval shunt; PVS, peritoneovenous shunt.
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Table 2. Preoperative and postoperative hemodynamic and renal functions in patients with hepatorenal syndrome
Patient
no.
Time of
testings
Wt
kg
Blood
pressure
Plasma
volume"
mi/kg
Blood urea
nitrogen
mg/di
Serum
creatinine
mg/dl
Urine
volume
mi/24 hr Ascites
1 Preoperative 57 70/40 77 130 4.0 430 ++++
8 yr post PCS 95 134/78 85" 17 1.0 2300 0
2 Preoperative 72 90/45 — 87 6.0 80 ++++
2wkspostPCSc 72 110/50 — 158 7.6 40 ++++
3 Preoperative 47 80/55 — 30 1.2 340 ++++
lwk post PCS 41 60/40 — 57 1.2 150 ++++
4 Preoperative 66 100/50 — 53 2.1 317 ++++
I yrpostMCS 54 140/70 — 14 0.9 1330 0
5 Preoperative 75 85/50 — 146 7.7 115 ++++
1 mo post MCSC 49 100/50 — 140 7.2 1380 +
6A Preoperative 83 110/70 46 38 1.9 446 + + + +
2 mos post PVS 74 115/70 65 12 0.9 1600 +
6B Preoperative 87 95/60 47 29 2.0 500 + + + +
l2mospostMCS 72 140/70 — 11 0.8 1800 ++
7 Preoperative 111 110/70 54 65 4.0 490 + + + +
6 wks post PVS 96 125/70 65 11 1.0 2340 + +
8 Preoperative 59 95/65 66 25 2.0 350 ++++
2 wks post PVS 46 105/65 77 7 0.6 2040 0"
9A Preoperative 50 80/50 52 22 1.2 350 ++++
1 mo post PVS 39 120/70 77 5 0.6 2200 ++
9B Preoperative 50 110/70 55 9 1.1 900 + + + +
2mospost2ndPyS 38 110/70 81 6 0.6 2300 ++
10 Preoperative 77 100/60 41 70 5.4 <200 ++++
3 mos post PVS 65 120/80 60 16 1.1 2500 +
Abbreviations are: PCS, side-to-side portacaval shunt; MCS, mesocaval shunt; PVS, peritoneovenous shunt.
Based on body weight minus estimated weight of ascites (normal range: 39 to 49 mllkg).
Patient died in the early postoperative period.
Eighteen months after surgery.
Ascites is graded from barely detectable by percussion (+) to massive, tense (++++).
40 C, and the plasma was frozen at _700 C until as-
sayed. PRS was determined on the same samples
using the method of Tree [191. The mean SD for
similarly obtained samples from normal subjects is
5.3 0.4ng/ml/hrforPRA and 1.2 0.61mole/liter
for PRS. Plasma volume was estimated by 1251albu-
min dilution. Evaluation of response to angiotensin
II (All) blockade with saralasin was performed as
previously described [201.
Results
Laboratory and clinical data are shown in Tables
1 and 2. In patients 2, 3, and 5, liver function wors-
ened in the early postoperative period, and liver
failure was the major cause of death. The two other
patients who had portacaval shunts as the primary
procedure (patients 1 and 4) are well and free of as-
cites 10 years and 2 years, respectively, after sur-
gery. Each of the other five patients in whom a pen-
toneovenous shunt was inserted recovered from
surgery without serious complication. Patient 7, how-
ever, later developed peritonitis and died 10 weeks
alter surgery. In patients 6 and 9, the pen-
toneovenous shunt clotted, necessitating a second
operation, as noted in Methods.
As shown in Table 2, blood pressure and daily
urine volume, which were low prior to surgery, in-
creased after surgery in each patient with the ex-
ception of patient 3. Serum creatinine and blood
urea nitrogen concentration decreased post-
operatively in seven patients. Postoperatively, six
patients underwent sustained spontaneous diuresis
and natriuresis, and nine patients became respon-
sive to diuretics. Plasma volume, measured in sev-
en patients, rose from a preoperative mean (± SE) of
56.0 4.6 ml/kg to a postoperative value of 73.0
3.6 mllkg (P < 0.001). In each of four patients (one
with a portacaval shunt and three with a pen-
toneovenous shunt), cardiac output rose and total
vascular resistance fell following surgery (Fig. 1).
Changes in creatinine clearance are shown in Fig.
2. Each preoperative value represents the mean of
from two to six determinations on 24-hour urine col-
lections. Postoperative values coincide with the lat-
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est serum creatinine samples obtained (see Table 2).
In the seven patients (involving nine procedures)
who recovered from surgery, creatinine clearance
rose from a mean SE of 19.0 3.2 mi/mm to 68.0
7.0 mI/mm (P < 0.001). The course in patients 6
and 9 is of particular interest. In each patient, after
initial improvement following insertion of the pen-
toneovenous shunt, the shunt clotted. Renal func-
tion deteriorated to preoperative levels (Fig. 2, pa-
tients 6B and 9B), plasma volume and cardiac out-
put decreased, and ascites reaccumulated (Table 2).
Following construction of a mesocaval shunt (pa-
tient 6B) and insertion of another peritoneovenous
shunt (patient 9B) renal function again improved to
approximately the previous postoperative level,
and ascites decreased. Witte et al [14] have reported
similar findings in a patient receiving sequential
peritoneovenous shunts.
Plasma renin activity (PRA) (Fig. 3) fell from a
mean SE of 41.0 8.2 ng/ml/hr before surgery to
2.3 0.8 ng/ml/hr after surgery (P < 0.001). In
those patients with a peritoneovenous shunt (pa-
tients 6-10), marked reduction in PRA occurred
within 8 hours after surgery, whereas in those with
a side-to-side portacaval shunt the changes oc-
curred over several days to weeks. In patients 6 and
9, when the peritoneovenous shunt clotted, PRA
rose, but was again suppressed to normal levels af-
ter the second surgical procedure (patients 6B and
9B). Fig. 4 shows examples of early postoperative
1200
1000
800
sequential changes in creatinine clearance and PRA
in one patient with a portacaval shunt and in two
patients with peritoneovenous shunts.
Figure 5 shows changes in plasma renin substrate
(PRS) assayed from samples identical to those test-
ed for PRA in eight patients. Substrate concentra-
tion increased from a preoperative mean SE of
0.34 0.12 JLM/liter to a postoperative value of 1.0
0.16 M/1iter (P < 0.005). The rise in PRS coin-
cided with the significant fall in PRA, and in all cas-
es with prolonged survival PRS achieved a normal
level. Serial PRS was measured in four patients
with peritoneovenous shunts. Within 24 hours PRS
rose from a preoperative mean SD of 0.3 0.3 to
0.6 0.4 M/liter following surgery, coinciding
with a marked fall in PRA. During this time, there
were no changes in laboratory tests of liver func-
tion. No renin substrate was detected in pre-
operative samples of ascitic fluid in these patients.
Changes in blood pressure and PRA in response
to All blockade with saralasin are shown in Fig. 6.
Before surgery, each patient tested was very sensi-
tive to All blockade, with marked hypotension oc-
curring at doses of saralasin as low as 0.1 ,.g/kg/
mm. Postoperatively, under comparable conditions
of restricted sodium intake, in each case blood pres-
100
80
E
0C
'I,
00C
C
(000
Pre
Fig. 2. Preoperative (Pre) and postoperative (Post) creatinine
clearance in patients with hepatorenal syndrome receiving a
side-to-side portacaval shunt (patients 1105 and patient 6B) or a
peritoneovenus shunt (patients 6 to 10).
0
6
>(0EE
12
10
80 /020
(00
140
120
- 100
0
80
Pre Post
600
Pre Post
Fig. 1. Preoperative (Pre) and postoperative (Post) herno-
dynamic measurements in patients with hepatorenal syndrome
receiving a peritoneovenous shunt or side-to-side portcaval
shunt.
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sure was unaffected by saralasin at a dose of up to
10 pgIkgImin. Similarly, before surgery, PRA rose
during All blockade, a response similar to that seen
in cirrhotics without renal failure [20]. After sur-
gery, PRA was unaffected by All blockade.
Discussion
Renal function improved, and the renin system
was significantly depressed in seven of our ten pa-
tients treated with either a portacaval shunt or a
peritoneovenous shunt who survived the early post-
operative period. Six of these patients are alive
from 2 months to 10 years after surgery, either in
improved condition or in good health. These results
confirm and extend previous observations [8-15]
but do not establish these procedures as effective
treatments for patients with hepatorenal syndrome
because this was not a controlled prospective
study. Our findings, along with those of others [9-
15], however, strongly suggest a causal relation be-
tween the surgical procedures and the rapid post-
operative improvement in renal function. The
mechanisms leading to improved renal function are
not clear, and the two types of surgery may have
many different physiologic effects. We focused our
study on the hemodynamic effects of these shunts
and coincident changes in the renin system, since
circulatory changes are thought to play a major role
in the hepatorenal syndrome, and All is known to
be a factor in the control of peripheral vascular re-
sistance in patients with cirrhosis and ascites [20].
In addition, All is thought to influence distribution
of renal blood flow under certain circumstances [21,
221.
Plasma volume and cardiac output rose after sur-
gery in our patients. Although preoperatively the
total plasma volume and cardiac output were not
low, it is possible that the arterial filling ("ef-
fective" plasma volume) was diminished, and that
the surgical procedures improved renal function
and suppressed the renin system by expanding the
20
I
20
Pre Post
Fig. 3. Changes in plasma renin activity (PRA) following con-
struction of a side-to-side portacaval shunt (patients I to 5 and
patient 6B) or insertion of a peritoneovenous shunt (patients 6 to
10) in patients with hepatorenal syndrome. Shaded area repre-
sents range for normal values. Values for each case represent the
mean of from three to six samples. Pre and Post refer to pre-
operative and postoperative.
30
5 Dayof 5 10 20
surgery
Time, days
Fig. 4. Sequential changes in creatinine clearance and plasma
renin activity (PRA) in patients with hepatorenal syndrome re-
ceiving a peritoneovenous shunt (O——O and A——s) or a
mesocaval shunt (S——•).
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"effective" plasma volume. Several clinical studies
support the concept of reduced "effective" plasma
volume as a factor in decreased renal function in
cirrhosis [4, 11, 23]. Epstein et al 1124] has shown
that immersion in water to the neck, a procedure
which causes redistribution of blood with expansion
of the central blood volume [251, improved renal
function and lowered PRA in patients with cirrhosis
and ascites. Further support for a role for low "ef-
fective" plasma volume can be found in the striking
similarities between our patients and dogs with low
cardiac output due to constriction of the thoracic
inferior vena cava (TIVC) 1126]. Watkins et al [271
have shown that in most dogs with constriction of
the TIVC, compensation for decreased arterial fill-
ing is accomplished by activation of the renin-angio-
tensin-aldosterone system, and acute blockade of
All in the compensated state produces marked
hypotension. Dogs with tight constriction of the
TIVC may not attain hemodynamic stability, in
spite of high PRA and plasma aldosterone, until the
constriction is removed, at which time blood pres-
sure, the renin system, and the response to All
blockade all return to normal. The striking similar-
-a
=0
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E
Co0
. . . . . .
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ities between the hemodynamic and hormonal
changes induced by surgery in our patients, and
those induced in dogs by removal of a tight con-
striction on the TIVC, suggest that in the hepato-
renal syndrome, as in the hemodynamically un-
stable dogs, decreased arterial filling is an important
factor.
In patients with cirrhosis and ascites, however,
including our patients before surgery, plasma vol-
ume may be normal or high, and there is no correla-
tion between total plasma volume or cardiac output
and renal hemodynamic changes [2, 3]. Also, the
rationale for decreased "effective" plasma volume
in cirrhosis is based on the assumption that ascites
forms at the expense of plasma volume. Careful
studies in patients [28] and in dogs with toxic liver
damage [29], however, indicate that, at least in the
early stages of cirrhosis, ascites formation results
from expansion of the extracellular fluid volume,
and accumulation of ascites does not compromise
the "effective" plasma volume. Also, Lieberman,
Ito, and Reynolds [30] have shown, in cirrhotics un-
dergoing spontaneous or induced diuresis, that
Preoperative Postoperative
100
80
60
40
20
90
80
70
60
50
40
E
0
0
Co0
I I
1.8
0 0.1 1 5 10 0 0.1 1 5 10
Saralasin, pg/kg/rn/n Saralasin, pg/kg/rn/n
Fig. 6. Comparison of preoperative and postoperative response
of plasma renin activity and mean blood pressure (BP) to iv.
infusion of the All analogue, saralasin, in patients with hepato-
renal syndrome receiving a side-to-side portacaval shunt or a
peritoneovenous shunt.
I
8
9A
6A
10
0.2
7
5
PostoperativePreoperative
Fig. 5. Changes in plasma renin substrate concentration follow-
ing construction of a side-to-side portacaval shunt (patients ito
5) or insertion of a peritoneovenous shunt (patients 6 to JO) in
patients with hepatorenal syndrome. Shaded area represents
range for normal values.
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changes in renal function are not accompanied by
changes in estimated "effective" plasma volume.
Finally, Ring-Larsen, Hesse, and Stigsby [311 have
shown that an end-to-side portacaval shunt does not
improve renal function in cirrhotic patients who do
not have overt renal failure. We have no ex-
planation which would reconcile these findings and
ours, except to suggest that factors which influence
ascites formation and renal function in advanced
cirrhosis with hepatorenal syndrome may differ
from those operative in earlier stages of cirrhosis.
Although the role of the renin system relative to
renal failure in cirrhosis remains unclear, under cer-
tain conditions All is important in support of blood
pressure in patients with cirrhosis [201, as shown by
the preoperative response to saralasin in our pa-
tients (Fig. 6). In cirrhosis, however, a deficiency of
plasma renin substrate (PRS), which is synthesized
by the liver, may limit All production. Before sur-
gery, PRS was below normal in all but one of our
patients (Fig. 5). A significant increase in PRS oc-
curred shortly after surgery, and there was an in-
verse correlation between PRS and PRA. This sug-
gests that in our patients with possibly limited he-
patic capacity to synthesize substrate, high levels of
PRA (possibly induced by renal cortical ischemia)
may deplete PRS by causing a rapid rate of sub-
strate proteolysis. Thus, a new steady state may be
established wherein a low level of PRS need not be
incompatible with generation of substantial amounts
of All. This is consistent with the observation by
Kondo et al [32] that plasma All levels in cirrhosis
parallel PRA levels and may be high even in the
presence of low PRS. Our data do not support the
suggestion of Berkowitz, Miller, and Rosato [33]
that low PRS may be a primary cause of renal
vasoconstriction in the hepatorenal syndrome.
In summary, our data extend previous observa-
tions showing that improvement in renal function
and normalization of the renin system occurs in
some patients with hepatorenal syndrome coinci-
dent with establishing a side-to-side portacaval
shunt or a peritoneovenous shunt. The efficacy of
these procedures in prolonging the survival of pa-
tients with hepatorenal syndrome remains to be
proven by controlled prospective study. Our study
does not conclusively define whether the changes in
the renin system are secondary to hemodynamic al-
terations or are important factors in the post-
operative improvement in hemodynamic stability,
nor does it provide any direct information con-
cerning changes in intrarenal vascular resistance,
which are critical in the hepatorenal syndrome. The
postoperative changes noted, and the similarities
between our patients with decompensated cirrhosis
and TIVC dogs with low cardiac output, however,
provide evidence that decreased "effective" blood
volume may be important in the stimulation of renin
release and possibly in the pathophysiology of renal
failure in the hepatorenal syndrome.
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